Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Withdrawn 2Recruiting 1

Sponsor Class

OTHER 177INDUSTRY 36OTHER_GOV 3NETWORK 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Gastrointestinal 1

Conditions

Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Cisplatin 118Radiotherapy 114Cyclophosphamide 93Paclitaxel 84Gemcitabine 74Carboplatin 67Filgrastim 60Doxorubicin 57Vincristine 56Etoposide 56Docetaxel 56Fluorouracil 51Cytarabine 41Prednisone 40Methotrexate 40Leucovorin 39Dexamethasone 37Capecitabine 36Irinotecan 35Rituximab 29Oxaliplatin 28Granulocyte Colony-Stimulating Factor 27Cetuximab 26Bevacizumab 26durvalumab 24Temozolomide 24Radiotherapy, Intensity-Modulated 24Peripheral Blood Stem Cell Transplantation 24Magnetic Resonance Spectroscopy 24Surgical Procedures, Operative 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × NETWORK × lenvatinib × Clear all
NCT06880523 2026-04-14

SLIDE-HCC

Canadian Cancer Trials Group

Phase 2 Recruiting
140 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT06068153 2024-11-20

AMBER

ETOP IBCSG Partners Foundation

Phase 2 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03005015 2016-12-29

Lenvatinib in Second Line Endometrial Carcinoma

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Withdrawn
Gynecologic

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡